Mga Batayang Estadistika
| CIK | 1580149 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioVie Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 15, 2025 |
Exhibit 97.1 BIOVIE INC. CLAWBACK POLICY Purpose BioVie Inc. (the “Company”) is establishing this policy to align the interests of executive officers of the Company with those of shareholders, to create and maintain a culture that emphasizes integrity and accountability and to enforce the Company’s pay-for-performance compensation philosophy. This policy provides for the recoupment of certain exec |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE FISCAL YEAR ENDED JUNE 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE INC. (Exact name of |
|
| August 15, 2025 |
Amended and Restated Bylaws of the Company, adopted on May 28, 2025. Exhibit 3.9 AMENDED AND RESTATED BYLAWS OF BIOVIE, INC. (Adopted on May 28, 2025) ARTICLE I OFFICES SECTION 1. REGISTERED OFFICE. The registered office of BioVie, Inc. (the “Corporation”) in Nevada shall be that of its registered agent most recently appointed in the Articles of Incorporation, or as evidenced by a certificate of acceptance executed by a registered agent and filed with the Secretary |
|
| August 15, 2025 |
BioVie Inc. Insider Trading Policy Exhibit 19.1 BIOVIE INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Company Securities Adopted: March 1, 2021 In order to take an active role in the prevention of insider trading violations by its directors, officers and other employees, as well as by other related individuals, BioVie Inc (the “Company”) has adopted the policies and procedures described in this M |
|
| August 11, 2025 |
BioVie Inc. Announces Closing of $12 Million Public Offering EXHIBIT 99.2 BioVie Inc. Announces Closing of $12 Million Public Offering Carson City, Nevada, August 11, 2025 - BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously |
|
| August 11, 2025 |
EXHIBIT 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOVIE INC. Warrant Shares: Issue Date: August 11, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and until t |
|
| August 11, 2025 |
Underwriting Agreement, dated as of August 7, 2025, by and between the Company and the Underwriter EXHIBIT 1.1 Execution Version UNDERWRITING AGREEMENT between BioVie Inc. and ThinkEquity LLC as Representative of the Several Underwriters UNDERWRITING AGREEMENT New York, New York August 7, 2025 ThinkEquity LLC as Representative of the several Underwriters named on Schedule 1 hereto 17 State Street, 22nd Floor New York, NY 10004 Ladies and Gentlemen: The undersigned, BioVie Inc., a Nevada corpora |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) August 7, 2025 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| August 11, 2025 |
Form of Underwriter’s Warrant. EXHIBIT 4.3 Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) |
|
| August 11, 2025 |
BioVie Inc. Announces Pricing of $12 Million Public Offering EXHIBIT 99.1 BioVie Inc. Announces Pricing of $12 Million Public Offering Carson City, Nevada, August 7, 2025 - BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritte |
|
| August 11, 2025 |
EXHIBIT 10.1 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of August 11, 2025 (the “Issuance Date”) between BioVie Inc., a Nevada corporation (the “Company”), and West Coast Stock Transfer, Inc., a California corporation (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (“Underwriting Agreement”), dated August 7, 2025 |
|
| August 8, 2025 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-288525 PROSPECTUS 5,620,000 Units, Each Consisting of One Share of Class A Common Stock and One Warrant to Purchase One Share of Class A Common Stock 380,000 Pre-Funded Units, Each Consisting of One Pre-Funded Warrant to Purchase One Share of Class A Common Stock and One Warrant to Purchase One Share of Class A Common Stock 6,000,000 |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOVIE INC. |
|
| August 4, 2025 |
As filed with the Securities and Exchange Commission on August 4, 2025. As filed with the Securities and Exchange Commission on August 4, 2025. Registration Statement No. 333-288525 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioVie Inc. (Exact name of registrant as specified in its charter) Nevada 2834 46-2510769 (State or Other Jurisdiction of Incorporation o |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) July 17, 2025 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| July 23, 2025 |
BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie’s mission Carson City, NV, July 22, 2025 – BioVie Inc. |
|
| July 22, 2025 |
As filed with the Securities and Exchange Commission on July 22, 2025. As filed with the Securities and Exchange Commission on July 22, 2025. Registration Statement No. 333-288525 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioVie Inc. (Exact name of registrant as specified in its charter) Nevada 2834 46-2510769 (State or Other Jurisdiction of Incorporation or |
|
| July 11, 2025 |
As filed with the Securities and Exchange Commission on July 11, 2025. As filed with the Securities and Exchange Commission on July 11, 2025. Registration Statement No. 333-288525 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioVie Inc. (Exact name of registrant as specified in its charter) Nevada 2834 46-2510769 (State or Other Jurisdiction of Incorporation or |
|
| July 3, 2025 |
Form of Representative’s Warrant Agreement (included as Exhibit A to Exhibit 1.1) Exhibit 1.1 UNDERWRITING AGREEMENT between BioVie Inc. and ThinkEquity LLC as Representative of the Several Underwriters UNDERWRITING AGREEMENT New York, New York [·], 2025 ThinkEquity LLC as Representative of the several Underwriters named on Schedule 1 hereto 17 State Street, 22nd Floor New York, NY 10004 Ladies and Gentlemen: The undersigned, BioVie Inc., a Nevada corporation (the ”Company”), h |
|
| July 3, 2025 |
Exhibit 21.1 Subsidiaries Entity Jurisdiction Option Therapeutics Inc. Delaware |
|
| July 3, 2025 |
As filed with the Securities and Exchange Commission on July 3, 2025. As filed with the Securities and Exchange Commission on July 3, 2025. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioVie Inc. (Exact name of registrant as specified in its charter) Nevada 2834 46-2510769 (State or Other Jurisdiction of Incorporation or Organization) (Primary |
|
| July 3, 2025 |
Form of Pre-Funded Common Stock Purchase Warrant Exhibit 4.17 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOVIE INC. Warrant Shares: Issue Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and until this Warr |
|
| July 3, 2025 |
Form of Warrant Agent Agreement Exhibit 4.20 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of , 2025 (the “Issuance Date”) between BioVie Inc., a Nevada corporation (the “Company”), and West Coast Stock Transfer, Inc., a California corporation (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (“Underwriting Agreement”), dated , 2025, by and between |
|
| July 3, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOVIE INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Units consisting |
|
| July 3, 2025 |
Form of Common Stock Purchase Warrant Exhibit 4.18 COMMON STOCK PURCHASE WARRANT biovie Inc. Warrant Shares: Initial Exercise Date: [ ], 2025 Issue Date: [ ], 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 BioVie Inc. (Exact name of registrant as specified in its charter) Nevada 001-39015 46-2510769 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 BioVie Inc. (Exact name of registrant as specified in its charter) Nevada 001-39015 46-2510769 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 15, 2025 |
As confidentially submitted to the Securities and Exchange Commission on May 14, 2025. |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE INC. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) March 28, 2025 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE I |
|
| December 31, 2024 |
CONSENT OF INDEPENDENT REGISTE EXHIBIT 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement of BioVie Inc. on Form 1-A to be filed on or about December 31, 2024, of our report dated September 30, 2024, on our audits of the financial statements as of June 30, 2024 and 2023 and for each of the years then ended, which report was included in the An |
|
| December 31, 2024 |
PLACEMENT AGENCY AGREEMENT [*], 2025 ThinkEquity LLC 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: Introductory. |
|
| December 31, 2024 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOVIE INC. PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOVIE INC. Warrant Shares: Issue Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and until this Warrant is exerci |
|
| December 31, 2024 |
Exhibit 12.1 9275 W. Russell Road, Suite 240 Las Vegas, Nevada 89148 PH (702) 692-8026 | FX (702) 692-8075 fennemorelaw.com December 31, 2024 BioVie Inc. 680 West Nye Lane, Suite 201 Carson City, Nevada 89703 Re: BioVie Inc./Regulation A Offering Statement on Form 1-A Ladies and Gentlemen: We have acted as special Nevada counsel to BioVie Inc., a Nevada corporation (the “Company”), in connection w |
|
| December 31, 2024 |
PRELIMINARY OFFERING CIRCULAR DATED DECEMBER 31, 2024 PRELIMINARY OFFERING CIRCULAR DATED DECEMBER 31, 2024 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. |
|
| December 2, 2024 |
Up to 7,711,613 Shares of Common Stock Offered by the Selling Stockholders Filed Pursuant to Rule 424(b)(3) Registration No. 333-283394 PROSPECTUS Up to 7,711,613 Shares of Common Stock Offered by the Selling Stockholders This prospectus relates to the offer and resale, from time to time, by the selling stockholders named under the heading “Selling Stockholders” in this prospectus (the “Selling Stockholders”), and their donees, pledgees, transferees or other successors-i |
|
| November 29, 2024 |
BioVie Inc. 680 W Nye Lane Suite 204 Carson City, NV 89703 BioVie Inc. 680 W Nye Lane Suite 204 Carson City, NV 89703 November 29, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Dickerson Re: BioVie Inc. Registration Statement on Form S-1 File No. 333-283394 Dear Ms. Dickerson: Pursuant to Rule 461 under the Securities Act of 1933, as am |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. |
|
| November 22, 2024 |
As filed with the Securities and Exchange Commission on November 22, 2024 As filed with the Securities and Exchange Commission on November 22, 2024 Registration No. |
|
| November 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BioVie Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo |
|
| November 21, 2024 |
As filed with the Securities and Exchange Commission on November 21, 2024 As filed with the Securities and Exchange Commission on November 21, 2024 Registration No. |
|
| November 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) BioVie Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) November 7, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| October 29, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-274083 PROSPECTUS SUPPLEMENT (To Prospectus dated August 28, 2023) 1,146,000 Shares of Class A Common Stock BioVie Inc. We are offering 1,146,000 shares (the “Shares”) of our Class A common stock, $0.0001 par value per share (our “Common Stock”), at an offering price of $2.83 per Share, pursuant to this prospectus supplement and the accompanyin |
|
| October 29, 2024 |
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Carson City, Nevada, October 28, 2024 - BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announ |
|
| October 29, 2024 |
Form of Placement Agent’s Warrant Agreement Exhibit 10.1 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. PLACEMENT AGENCY AGREEMENT October 28, 2024 ThinkEquity LLC 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 28, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| October 29, 2024 |
BioVie Inc. Announces Closing of Registered Direct Offering Exhibit 99.1 BioVie Inc. Announces Closing of Registered Direct Offering Carson City, Nevada, October 29, 2024 — BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announ |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 28, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| October 25, 2024 |
BIVI / BioVie Inc. / 3i, LP - SC 13G Passive Investment SC 13G 1 g084509sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BioVie Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 09074F405 (CUSIP Number) October 22, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| October 24, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 23, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| October 24, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-274083 PROSPECTUS SUPPLEMENT (To Prospectus dated August 28, 2023) 2,667,000 Shares of Class A Common Stock BioVie Inc. We are offering 2,667,000 shares (the “Shares”) of our Class A common stock, $0.0001 par value per share (our “Common Stock”), at an offering price of $2.25 per Share, pursuant to this prospectus supplement and the accompanyin |
|
| October 24, 2024 |
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement Exhibit 99.1 BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement Carson City, Nevada, October 24, 2024 — BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the |
|
| October 24, 2024 |
Form of Placement Agent’s Warrant Agreement Exhibit 10.1 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. PLACEMENT AGENCY AGREEMENT October 23, 2024 ThinkEquity LLC 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms |
|
| October 24, 2024 |
Exhibit 99.1 BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules Carson City, Nevada, October 23, 2024 - BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-deg |
|
| October 24, 2024 |
Form of Common Stock Purchase Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 23, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| October 22, 2024 |
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement Exhibit 99.1 BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement Carson City, Nevada, October 22, 2024 — BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the |
|
| October 22, 2024 |
Form of Common Stock Purchase Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 22, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 22, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| October 22, 2024 |
Exhibit 99.1 BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules Carson City, Nevada, October 21, 2024 - BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-deg |
|
| October 22, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-274083 PROSPECTUS SUPPLEMENT (To Prospectus dated August 28, 2023) 4,443,000 Shares of Class A Common Stock BioVie Inc. We are offering 4,443,000 shares (the “Shares”) of our Class A common stock, $0.0001 par value per share (our “Common Stock”), at an offering price of $1.50 per Share, pursuant to this prospectus supplement and the accompanyin |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 21, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| October 22, 2024 |
Form of Placement Agent’s Warrant Agreement Exhibit 10.1 PLACEMENT AGENCY AGREEMENT October 21, 2024 ThinkEquity LLC 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity” or the “Placement Agent”) shall be engaged by BioVie Inc., a Nevada corporation (the “Company”), to act as the exclusive Placement Age |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE FISCAL YEAR ENDED JUNE 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE INC. (Exact name of |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| September 25, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 25, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| September 25, 2024 |
BioVie Inc. Announces Closing of Public Offering EX-99.1 2 bivi-202409258kex99z1.htm EXHIBIT 99.1 BioVie Inc. Announces Closing of Public Offering Carson City, Nevada, September 25, 2024 — BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closi |
|
| September 25, 2024 |
The date of this prospectus supplement is September 25, 2024 Filed Pursuant to Rule 424(b)(5) Registration No. 333-274083 SUPPLEMENT To Prospectus Supplement dated January 19, 2024 (To Prospectus Dated August 28, 2023) This supplement to the prospectus supplement (this “Supplement”) amends and supplements the prospectus supplement, dated January 19, 2024 (the “Prospectus Supplement”), relating to the offer and sale of shares of our Class A common stock, par |
|
| September 24, 2024 |
Form of Placement Agent’s Warrant Agreement PLACEMENT AGENCY AGREEMENT September 23, 2024 ThinkEquity LLC 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: Introductory. |
|
| September 24, 2024 |
BioVie Inc. Announces Proposed Public Offering BioVie Inc. Announces Proposed Public Offering Carson City, Nevada – September 23, 2024 – BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded war |
|
| September 24, 2024 |
BioVie Inc. Announces Pricing of Public Offering BioVie Inc. Announces Pricing of Public Offering Carson City, Nevada, September 23, 2024 - BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a best efforts public offering of 1,960,800 |
|
| September 24, 2024 |
Form of Pre-Funded Common Stock Purchase Warrant PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOVIE INC. Warrant Shares: Issue Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and until this Warrant is exerci |
|
| September 24, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 23, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 23, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| September 24, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-274083 1,360,800 Shares of Class A Common Stock Pre-funded Warrants to Purchase up to 600,000 Shares of Class A Common Stock Warrants to Purchase up to 1,960,800 Shares of Class A Common Stock BioVie Inc. We are offering 1,360,800 shares (the “Shares”) of our Class A common stock, $0.0001 par value per share (our “Common Stock”), at an offering |
|
| September 24, 2024 |
Form of Common Stock Purchase Warrant COMMON STOCK PURCHASE WARRANT biovie Inc. Warrant Shares: Initial Exercise Date: September [ ], 2024 Issue Date: September [ ], 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here |
|
| September 23, 2024 |
ThinkEquity The date of this prospectus supplement is , 2024 TABLE OF CONTENTS PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No. 333-274083 The information in this prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with and declared effective by the Securities Exchange Commission. This prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soli |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 BioVie Inc. (Exact name of registrant as specified in its charter) Nevada 001-39015 46-2510769 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 BioVie Inc. (Exact name of registrant as specified in its charter) Nevada 001-39015 46-2510769 (State or other jurisdiction of incorporation) (Commi |
|
| August 6, 2024 |
Exhibit 3.2 |
|
| August 6, 2024 |
Termination of Amendment/Certificate Exhibit 3.1 |
|
| August 1, 2024 |
Exhibit 31.1 |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 BioVie Inc. (Exact name of registrant as specified in its charter) Nevada 001-39015 46-2510769 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 BioVie Inc. (Exact name of registrant as specified in its charter) Nevada 001-39015 46-2510769 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| June 25, 2024 |
BIVI / BioVie Inc. / Acuitas Group Holdings, LLC - SC 13D/A Activist Investment SC 13D/A 1 tm2418170d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* BIOVIE INC. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 09074F 207 (CUSIP Number) Terren S. Peizer Acuitas Group Holdings, LLC 200 Dorado Beach Drive #3831 |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE INC. |
|
| April 19, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) April 18, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| March 15, 2024 |
BIOVIE INC. 680 W Nye Lane, Suite 204 Carson City, NV 89703 BIOVIE INC. 680 W Nye Lane, Suite 204 Carson City, NV 89703 March 15, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Office of Life Sciences Re: BIOVIE INC. Form 10-K for the Fiscal Year Ended June 30, 2023 Filed August 16, 2023 File No. 001-39015 Ladies and Gentlemen: On behalf of BioVie Inc. (the “Compa |
|
| March 11, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) March 11, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| March 11, 2024 |
Exhibit 99.1 BioVie Announces Pipeline Update and Near-Term Clinical Priorities Recently completed financing provides sufficient funds for near-term Parkinson’s Disease priority Plans for Phase 2b trial of NE3107 as first-line monotherapy for Parkinson’s Disease being finalized with targeted launch late-summer 2024 Once-daily NE3107 formulation expected to be available early 2025 and will be used |
|
| March 6, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) March 6, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| March 6, 2024 |
Exhibit 99.2 |
|
| March 6, 2024 |
BioVie Inc. Announces Closing of Public Offering Exhibit 99.1 BioVie Inc. Announces Closing of Public Offering Carson City, Nevada, March 6, 2024 — BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced best effor |
|
| March 4, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) March 4, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| March 4, 2024 |
Per Share of Common Stock and Accompanying Common Warrant Filed Pursuant to Rule 424(b)(5) Registration No. 333-274083 PROSPECTUS SUPPLEMENT (To the Prospectus Dated August 28, 2023) 15,000,000 Shares of Class A Common Stock Pre-funded Warrants to Purchase up to 6,000,000 Shares of Class A Common Stock Warrants to Purchase up to 10,500,000 Shares of Class A Common Stock BioVie Inc. We are offering 15,000,000 shares (the “Shares”) of our Class A common st |
|
| March 4, 2024 |
Form of Pre-Funded Common Stock Purchase Warrant Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOVIE INC. Warrant Shares: Issue Date: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and until this Warrant is e |
|
| March 4, 2024 |
BioVie Inc. Announces Pricing of Public Offering Exhibit 99.2 BioVie Inc. Announces Pricing of Public Offering Carson City, Nevada, March 4, 2024 - BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its best efforts public offering of |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) March 4, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| March 4, 2024 |
Form of Placement Agent’s Warrant Agreement Exhibit 10.1 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. PLACEMENT AGENCY AGREEMENT ThinkEquity LLC March 4, 2024 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms up |
|
| March 4, 2024 |
BioVie Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 BioVie Inc. Announces Proposed Public Offering of Common Stock Carson City, Nevada – March 1, 2024 – BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that it intends to offer to sell shares of its common stoc |
|
| March 4, 2024 |
Form of Common Stock Purchase Warrant Exhibit 4.2 COMMON STOCK PURCHASE WARRANT biovie, Inc. Warrant Shares: Initial Exercise Date: March [ ], 2024 Issue Date: March [ ], 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| March 1, 2024 |
ThinkEquity The date of this prospectus supplement is March , 2024 Filed Pursuant to Rule 424(b)(5) Registration No. 333-274083 The information in this prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with and declared effective by the Securities Exchange Commission. This prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soli |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) March 1, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| March 1, 2024 |
BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 Data from Phase 2a trial in Parkinson’s Disease suggest patients treated with NE3107 experienced significant im |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE I |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) January 19, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) January 19, 2024 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| January 19, 2024 |
Up to $25,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-274083 PROSPECTUS SUPPLEMENT (To the Prospectus Dated August 28, 2023) Up to $25,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”), with Cantor Fitzgerald & Co. (“Cantor”), relating to shares of our Class A common stock (“common stock”) offered by this prospectus supplement and the |
|
| November 29, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) November 29, 2023 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 29, 2023 |
BioVie Announces EfficacyData from Phase 3 Trial of NE3107 in Patientswith Mild to Moderate Alzheimer’s Disease Positive TrendingData from 57 Per-Protocol PatientsSuggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker Endpoints Sponsor Identified Issues Relating to SignificantGCPViolations and Protocol Deviations, Which Allowed for Data from Only a Subset |
|
| November 29, 2023 |
Investor Presentation dated November 29, 2023. Exhibit 99.2 |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) November 8, 2023 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE |
|
| October 25, 2023 |
FOR RELEASE OCTOBER 25, 2023 AT 12:20PM ET Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients · Statistically significant population changes from baseline were observed for all primary and secondary cognitive and functional assessments measured: ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, and ADL. |
|
| October 25, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2023 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 8, 2023 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| September 11, 2023 |
Investor Presentation dated September 8, 2023 Exhibit 99.1 |
|
| August 29, 2023 |
PROSPECTUS Filed Pursuant to Rule 424(b)(3) File No. 333-274083 Primary Offering of $300,000,000 Class A Common Stock Preferred Stock Warrants Debt Securities Rights Units and Secondary Offering of Up to 311,002 Shares of Class A Common Stock Offered by the Selling Stockholders This prospectus relates to the offer and sale, from time to time, by BioVie Inc. (“we,” “us,” or the “Company”), in one o |
|
| August 24, 2023 |
BioVie Inc. 680 W Nye Lane Suite 204 Carson City, NV 89703 BioVie Inc. 680 W Nye Lane Suite 204 Carson City, NV 89703 August 24, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Gama Re: BioVie Inc. Registration Statement on Form S-3 File No. 333-274083 Dear Ms. Gama: Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioVie |
|
| August 18, 2023 |
As filed with the Securities and Exchange Commission on August 18, 2023 As filed with the Securities and Exchange Commission on August 18, 2023 Registration No. |
|
| August 18, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BioVie Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwa |
|
| August 18, 2023 |
Form of Indenture for Subordinated Debt Securities. Exhibit 4.6 BIOVIE INC. Company AND [TRUSTEE] Trustee INDENTURE Dated as of [·], 20[·] Subordinated Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee’s Certificate. 7 Se |
|
| August 18, 2023 |
Form of Indenture for Senior Debt Securities. EXHIBIT 4.5 BIOVIE, INC. Issuer AND [TRUSTEE] Trustee INDENTURE Dated as of [·], 20[·] Senior Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee’s Certificate. 7 Section |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE FISCAL YEAR ENDED JUNE 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE INC. (Exact name of |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE INC. |
|
| April 14, 2023 |
Up to 85,175 Shares of Common Stock Offered by the Selling Stockholders Filed Pursuant to Rule 424(b)(3) Registration No. 333-271054 PROSPECTUS Up to 85,175 Shares of Common Stock Offered by the Selling Stockholders This prospectus relates to the offer and resale, from time to time, by the selling stockholders named under the heading “Selling Stockholders” in this prospectus (the “Selling Stockholders”), and their donees, pledgees, transferees or other successors-in- |
|
| April 7, 2023 |
Up to $17,500,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-252386 PROSPECTUS SUPPLEMENT (To the Prospectus Dated February 2, 2021) Up to $17,500,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”), with Cantor Fitzgerald & Co. (“Cantor”), relating to shares of our Class A common stock (“common stock”) offered by this prospectus supplement and the |
|
| April 7, 2023 |
BioVie Inc. 680 W Nye Lane Suite 204 Carson City, NV 89703 BioVie Inc. 680 W Nye Lane Suite 204 Carson City, NV 89703 April 7, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: BioVie Inc. Registration Statement on Form S-3 File No. 333-271054 Dear Mr. McNamara: Pursuant to Rule 461 under the Securities Act of 1933, as amended, B |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) April 6, 2023 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| April 6, 2023 |
BioVie Inc. 680 W Nye Lane Suite 204 Carson City, NV 89703 BioVie Inc. 680 W Nye Lane Suite 204 Carson City, NV 89703 April 6, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: Mondee Holdings, Inc. Registration Statement on Form S-3 File No. 333-271054 Dear Mr. McNamara: Pursuant to Rule 461 under the Securities Act of 1933, as |
|
| March 31, 2023 |
Form of Underwriting Agreement. EX-1.1 2 bivis3ex1z1.htm EXHIBIT 1.1 UNDERWRITING AGREEMENT between BIOVIE INC. And THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. KINGSWOOD CAPITAL MARKETS DIVISION OF BENCHMARK INVESTMENTS, INC. as Representative of the Several Underwriters BIOVIE, INC. UNDERWRITING AGREEMENT New York, New York September 17, 2020 ThinkEquity A Division of Fordham Financial Management, Inc. 17 State |
|
| March 31, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BioVie Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Security(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration |
|
| March 31, 2023 |
As filed with the Securities and Exchange Commission on March 31, 2023 As filed with the Securities and Exchange Commission on March 31, 2023 Registration No. |
|
| March 31, 2023 |
EXHIBIT A Form of Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) [THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. |
|
| March 23, 2023 | ||
| March 23, 2023 |
BioVie Day Presentation March 23, 2023©2022 BioVie Inc. Forward-looking statements This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause BioVie’s actual results and experience to differ materially from anticipated results and expectation |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) March 23, 2023 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2023 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| March 13, 2023 |
First Amendment to the Amended and Restated Bylaws of the Company, dated March 12, 2023 FIRST AMENDMENT TO BYLAWS OF BIOVIE INC. Adopted on March 12, 2023 The Bylaws of BioVie Inc. (the “Corporation) are amended as follows: Article III, Section 1 is amended in its entirety to read as follows: Section 1. Number and Term. The number of directors of the Corporation shall be fixed as the Board of Directors may from time-to-time designate, provided that the number of members of the Board |
|
| March 10, 2023 |
BIVI / BioVie Inc / Acuitas Group Holdings, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* BIOVIE INC. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 09074F 207 (CUSIP Number) Terren S. Peizer Acuitas Group Holdings, LLC 200 Dorado Beach Drive #3831 Dorado, Puerto Rico 00646 310-444-4321 (Nam |
|
| March 7, 2023 |
BIVI / BioVie Inc / Acuitas Group Holdings, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* BIOVIE INC. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 09074F 207 (CUSIP Number) Terren S. Peizer Acuitas Group Holdings, LLC 200 Dorado Beach Drive #3831 Dorado, Puerto Rico 00646 310-444-4321 (Nam |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2023 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31,2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE IN |
|
| February 10, 2023 |
Exhibit 10.1 AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT THIS AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT (this “Amendment”) is made and entered into as of January 13, 2023, by and among BioVie Inc., a Nevada corporation (“Buyer”), Acuitas Group Holdings, LLC, a California limited liability company (as successor to NeurMedix, Inc., a Delaware corporation) (“Seller”), and Acuitas Group Holdings, LL |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) December 23, 2022 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| December 23, 2022 |
Up to $17,500,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-252386 PROSPECTUS SUPPLEMENT (To the Prospectus Dated February 2, 2021) Up to $17,500,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”), with Cantor Fitzgerald & Co. (“Cantor”) and B. Riley Securities, Inc. (“B. Riley Securities”), relating to shares of our Class A common stock (“common |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) December 14, 2022 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| December 15, 2022 |
Up to $17,500,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-252386 PROSPECTUS SUPPLEMENT (To the Prospectus Dated February 2, 2021) Up to $17,500,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”), with Cantor Fitzgerald & Co. (“Cantor”) and B. Riley Securities, Inc. (“B. Riley Securities”), relating to shares of our Class A common stock (“common |
|
| December 12, 2022 |
BioVie Inc. 680 W Nye Lane Suite 204 Carson City, NV 89703 RW 1 bivi-20221212rw.htm RW BioVie Inc. 680 W Nye Lane Suite 204 Carson City, NV 89703 VIA EDGAR December 12, 2022 U.S. Securities & Exchange Commission Division of Corporation Finance Office of Energy & Transportation 100 F Street, NE Washington, D.C. 20549 Attn: Lauren Hamill Re: BioVie Inc. (CIK 0001580149) Registration Statement on Form S-1 Dear Ms. Hamill: Pursuant to Rule 477 under the Secur |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) December 7, 2022 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| December 7, 2022 |
BioVie Issues Letter to Shareholders Exhibit 99.2 BioVie Issues Letter to Shareholders · Parkinson’s disease (PD) patients treated with NE3107 for 28 days experienced a clinically meaningful increase in motor control. · Additional data presented at the Clinical Trials in Alzheimer’s Disease (CTAD) conference showed that NE3107 enhanced cognition as measured by a variety of assessment tools. Furthermore, a large majority of patients w |
|
| December 7, 2022 |
Investor Presentation dated December 2022. Exhibit 99.1 |
|
| December 6, 2022 |
Up to $17,500,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-252386 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated August 31, 2022 and Prospectus Dated February 2, 2021) Up to $17,500,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated February 2, 2021, filed with the Securities and Exchange Commission as a part of our registration statement |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) December 5, 2022 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| December 6, 2022 |
Exhibit 99.2 BioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia Initial Data shows NE3107 may Reduce Horvath DNA Methylation SkinBlood Clock by 3.3 years after 3 months of treatment Carson City, NV, December 6, 2022 – BioVie Inc., (NASDAQ: |
|
| December 6, 2022 |
BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials Exhibit 99.1 BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials NE3107-treated patients experienced greater motor control in Parkinson’s trial ● Patients treated with the combination of NE3107 and levodopa saw improvements in their UPDRS Part 3 (motor) score that is 3+ points superior to patients treated with levodopa alone. This level of superiority is cons |
|
| December 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) December 6, 2022 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) BioVie Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee C |
|
| November 10, 2022 |
As filed with the U.S. Securities and Exchange Commission on November 10, 2022 As filed with the U.S. Securities and Exchange Commission on November 10, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioVie Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 2834 46-2510769 (State or other jurisdiction of incorporation or organization) (Primary |
|
| November 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) November 9, 2022 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 4, 2022 |
Exhibit 10.2 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of August 15, 2022 by and between BioVie Inc., a Nevada corporation (the “Company”), and Acuitas Group Holdings, LLC, a California limited liability company (“Acuitas”). The Company and Acuitas are sometimes collectively referred to |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE |
|
| October 5, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 4, 2022 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| October 5, 2022 |
BioVie Issues Letter to Shareholders Exhibit 99.1 BioVie Issues Letter to Shareholders ? Positive preliminary data from investigator-sponsored Phase 2 Alzheimer?s trial show high proportion of responders and level of cognitive improvements seen for NE3107 confirm NE3107?s status as one of the most promising candidates in the Alzheimer?s space ? Potentially pivotal Phase 3 trial for NE3107 in Alzheimer?s has enrolled over half the tar |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| September 30, 2022 |
424B5 1 bivi-20220930424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-252386 PROSPECTUS SUPPLEMENT (To the Prospectus Supplement dated August 31, 2022 To Prospectus Dated February 2, 2021) Up to $8,100,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated February 2, 2021, filed with the Securities and Exchange Commission a |
|
| September 27, 2022 |
Exhibit 21.1 BioVie Inc. Subsidiaries None. |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE FISCAL YEAR ENDED JUNE 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE INC. (Exact name of |
|
| September 7, 2022 |
EX-99.1 2 bivi-202209078kex99z1.htm EX-99.1 Exhibit 99.1 BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’s Disease BioVie Provides Updates on Other Clinical Programs ● Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression |
|
| September 7, 2022 |
Exhibit 99.1 BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’s Disease BioVie Provides Updates on Other Clinical Programs ● Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression of patient’s daily abilities) with NE3107 t |
|
| September 7, 2022 |
Exhibit 99.2 |
|
| September 7, 2022 |
Slide Presentation of BioVie Inc. Exhibit 99.2 |
|
| September 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 7, 2022 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 7, 2022 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| August 31, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) August 31, 2022 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| August 31, 2022 |
Up to $20,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-252386 PROSPECTUS SUPPLEMENT (To the Prospectus Dated February 2, 2021) Up to $20,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement (the ?Sales Agreement?), with Cantor Fitzgerald & Co. (?Cantor?) and B. Riley Securities, Inc. (?B. Riley Securities?), relating to shares of our Class A common stock (?common |
|
| August 31, 2022 |
EX-1.1 2 bivi-202208318kex1z1.htm EXHIBIT 1.1 Exhibit 1.1 BIOVIE INC. Shares of Class A Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement August 31, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: BioVie Inc., a Nevada corporation (the “Company”), con |
|
| August 16, 2022 |
BIVI / BioVie Inc / Acuitas Group Holdings, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* BIOVIE INC. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 09074F 207 (CUSIP Number) Terren S. Peizer Acuitas Group Holdings, LLC 2120 Colorado Avenue, #230 Santa Monica, California 90404 310-444-4321 ( |
|
| August 16, 2022 |
Exhibit 10.8 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of August 15, 2022 by and between BioVie Inc., a Nevada corporation (the ?Company?), and Acuitas Group Holdings, LLC, a California limited liability company (?Acuitas?). The Company and Acuitas are sometimes collectively referred to |
|
| August 16, 2022 |
Exhibit 10.6 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 15, 2022, between BioVie Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions set forth in |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement BIOVIE INC. (Name of Registrant as |
|
| July 18, 2022 |
Form of Common Stock Purchase Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) July 15, 2022 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 18, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 15, 2022, between BioVie Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions set forth in |
|
| July 15, 2022 |
BIVI / BioVie Inc / Acuitas Group Holdings, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* BIOVIE INC. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 09074F 207 (CUSIP Number) Terren S. Peizer Acuitas Group Holdings, LLC 2120 Colorado Avenue, #230 Santa Monica, California 90404 310-444-4321 ( |
|
| July 15, 2022 |
Form of Common Stock Purchase Warrant Exhibit 10.7 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 15, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 15, 2022, between BioVie Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions set forth in |
|
| July 15, 2022 |
Form of Common Stock Purchase Warrant. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement BIOVIE INC. (Name of Registrant as |
|
| July 15, 2022 |
Exhibit 10.6 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 15, 2022, between BioVie Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions set forth in |
|
| July 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) July 15, 2022 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| June 29, 2022 |
Developing Transformative Therapies to Overcome Chronic Debilitating Diseases Corporate Presentation ? June 2022 ?2022 BioVie Inc. |
|
| June 29, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) June 28, 2022 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-39015 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE INC. |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE I |
|
| December 1, 2021 |
BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. Reno, NV, December 1, 2021 ? BioVie Inc., (NASDAQ: BIVI) (?BioVie? or the ?Company?) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, entered into a d |
|
| December 1, 2021 |
Execution Copy SUPPLEMENT to the Loan and Security Agreement dated as of November 30, 2021 between BioVie Inc. |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) November 30, 2021 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-55292 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| December 1, 2021 |
Form of Warrant to Purchase Shares of Class A Common Stock of the Company THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?) OR ANY STATE SECURITIES LAWS. |
|
| December 1, 2021 |
Execution Copy LOAN AND SECURITY AGREEMENT Dated as of November 30, 2021 between BIOVIE INC. |
|
| November 10, 2021 |
Employment Offer & Agreement, between Chris Reading and the Company, dated June 18, 2021 June 18, 2021 Dr. Chris Reading 5833 Cozzens Street San Diego, CA 92122 Re: Offer of Employment Dear Chris, BIOVIE, INC., a Nevada corporation (the ?Company?) is pleased to offer you the position of Executive Vice President, Neuroscience Research & Development on the following terms. You will be responsible for efforts to advance the development of the NE3107 and the portfolio with particular emph |
|
| November 10, 2021 |
Employment Offer & Agreement, between Penelope Markham and the Company, dated September 7, 2021 August 23, 2021 Dr. Penelope Markham 6405 Woodland Run Ct Clifton, VA 20124 Re: Employment Agreements Dear Penny: BioVie, Inc., a Nevada corporation (the ?Company?) is pleased to offer you the position of Executive Vice President, Liver Disease Research and Development, on the following terms. You will be responsible for leading the scientific for our liver disease programs and will report to Cuon |
|
| November 10, 2021 |
Employment Offer & Agreement, between Joseph Palumbo and the Company, dated September 3, 2021 September 3, 2021 Dr. Joseph M. Palumbo 616 Brookside Avenue Saint Davids, PA 19087 Re: Updated Offer of Employment Dear Dr. Palumbo: BioVie, Inc., a Nevada corporation (the ?Company?) is pleased to offer you the position of Executive Vice President and Chief Medical Officer, on the following terms. You will be responsible for overseeing the clinical development efforts for all of the Company?s as |
|
| November 10, 2021 |
Exhibit 3.5 Amended and Restated Bylaws of the Company, dated June 16, 2020 |
|
| November 10, 2021 |
Employment Offer & Agreement, between Joanne Wendy Kim and the Company, dated June 26, 2021 June 19, 2021 Wendy Kim 501 Beale Street 20B San Francisco, CA 94105 Re: Employment Agreement Dear Wendy, BioVie, Inc. |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE |
|
| November 10, 2021 |
Employment Offer & Agreement, between Clarence Ahlem and the Company, dated June 18, 2021 June 17, 2021 Dr. Clarence Ahlem 5305 Renaissance Ave San Diego, CA 92122 Re: Offer of Employment Dear Clarence, BIOVIE, INC., a Nevada corporation (the ?Company?) is pleased to offer you the position of Executive Vice President, Product Development on the following terms. You will be responsible for efforts to advance the development of the NE3107 and the portfolio with particular emphasis on lau |
|
| November 10, 2021 |
August 21, 2021 Jonathan Adams 25 West 15th St, Unit B Chicago, IL 60605 Re: Employment Agreement Dear Jonathan, BioVie, Inc. |
|
| October 14, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 13, 2021 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-55292 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| October 4, 2021 |
As filed with the Securities and Exchange Commission on October 4, 2021 As filed with the Securities and Exchange Commission on October 4, 2021 Registration No. |
|
| September 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| August 30, 2021 |
Exhibit 4.4 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 References to ?BioVie? and the ?Company? herein are, unless the context otherwise indicates, only to BioVie Inc. and not to any of its subsidiaries. The following description of the Company?s capital stock and provisions of the Company?s Articles of Incorporation, bylaws and |
|
| August 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE FISCAL YEAR ENDED JUNE 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE INC. (Exact name of |
|
| August 11, 2021 |
BioVie Inc. Announces Closing of Public Offering of Common Stock BioVie Inc. Announces Closing of Public Offering of Common Stock SANTA MONICA, Calif., August 11, 2021 (GLOBE NEWSWIRE) ? BioVie Inc., (NASDAQ: BIVI) (?BioVie? or the ?Company?) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced the closing of its underwritten public off |
|
| August 11, 2021 |
UNDERWRITING AGREEMENT between BIOVIE INC. and THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC., as Representative of the Several Underwriters -1- BIOVIE INC. UNDERWRITING AGREEMENT New York, New York August 8, 2021 ThinkEquity A Division of Fordham Financial Management, Inc. As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 22nd Fl New |
|
| August 11, 2021 |
BioVie Inc. Announces Pricing of Public Offering of Common Stock BioVie Inc. Announces Pricing of Public Offering of Common Stock SANTA MONICA, Calif., August 8, 2021 (GLOBE NEWSWIRE) ? BioVie Inc., (NASDAQ: BIVI) (?BioVie? or the ?Company?) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced the pricing of its underwritten public offe |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) August 8, 2021 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-55292 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| August 10, 2021 |
The date of this prospectus supplement is August 8, 2021 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-252386 PROSPECTUS SUPPLEMENT (To the Prospectus Dated February 2, 2021) 2,500,000 Shares Common Stock BioVie Inc. We are offering 2,500,000 shares of Class A common stock, $0.0001 par value per share, which we refer to as our common stock. The purchase price for each share is $8.00. The common stock is listed on the Nasdaq Capital Market (the ? |
|
| August 6, 2021 | ||
| August 6, 2021 |
The date of this prospectus supplement is , 2021 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-252386 The information in this preliminary prospectus supplement, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to |
|
| August 5, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) August 5, 2021 BioVie Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-55292 46-2510769 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| August 5, 2021 |
BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer’s Disease BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer?s Disease SANTA MONICA, Calif. |
|
| June 11, 2021 |
BIVI / BioVie Inc / PEIZER TERREN S - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* BIOVIE INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09074F 108 (CUSIP Number of Class of Securities) Terren S. Peizer Acuitas Group Holdings, LLC 2120 Colorado Avenue, #230 Santa Monica, California 90404 |
|
| June 11, 2021 |
BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix Company Expects to Commence Enrollment in Pivotal Phase 3 Alzheimer's Trial in Mid-2021 SANTA MONICA, Calif. |
|
| June 11, 2021 |
Letter Agreement, dated as of June 10, 2021, between NeurMedix, Inc. and BioVie Inc. Exhibit 10.4 June 10, 2021 VIA EMAIL BioVie Inc. 2120 Colorado Avenue, Suite 230 Santa Monica, CA 90404 Attention: Cuong V. Do Re: Asset Purchase Agreement Dear Mr. Do: Reference is made to that certain Asset Purchase Agreement, dated as of April 27, 2021 (as amended, the ?Agreement?), by and among BioVie Inc. (?BioVie?), NeurMedix, Inc. (?NeurMedix?) and, solely for purposes of Section 10.16 ther |
|
| June 11, 2021 |
REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of June 10, 2021 by and between BioVie Inc. |
|
| June 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 BioVie Inc. (Exact name of registrant as specified in its charter) Nevada 001-39015 46-2510769 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| June 11, 2021 |
Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of June 10, 2021 by and between BioVie Inc., a Nevada corporation (the ?Company?), and Acuitas Group Holdings, LLC, a California limited liability company (?Acuitas?). The Company and Acuitas are sometimes collectively referred to herein as the ?Parties? and each is sometime |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement BIOVIE INC. (Name of Registrant as Specified in its |
|
| May 17, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 BioVie Inc. (Exact name of registrant as specified in its charter) Nevada 001-39015 46-2510769 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| May 17, 2021 | ||
| May 17, 2021 | ||
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2021 BioVie Inc. (Exact name of registrant as specified in its charter) Nevada 001-39015 46-2510769 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 10, 2021 |
BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix SANTA MONICA, Calif. |
|
| May 10, 2021 |
Exhibit 10.3 EXECUTION VERSION AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT (this ?Amendment?) is made and entered into as of May 9, 2021 by and among BioVie Inc., a Nevada corporation (?Buyer?), NeurMedix, Inc., a Delaware corporation (?Seller?), and Acuitas Group Holdings, LLC, a California limited liability company (?Guarantor?), solely for purpos |
|
| May 10, 2021 |
AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT (this ?Amendment?) is made and entered into as of May 9, 2021 by and among BioVie Inc., a Nevada corporation (?Buyer?), NeurMedix, Inc., a Delaware corporation (?Seller?), and Acuitas Group Holdings, LLC, a California limited liability company (?Guarantor?), solely for purposes of Section 10.16 of the Agre |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. 1) Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement BIOVIE INC. (Name of Registrant as |
|
| May 10, 2021 |
Quarterly Report - FORM 10-Q FOR PERIOD ENDING MARCH 31, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39015 BIOVIE INC. |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* BIOVIE INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09074F 108 (CUSIP Number of Class of Securities) Terren S. Peizer Acuitas Group Holdings, LLC 2120 Colorado Avenue, #230 Santa Monica, California 90404 |
